Spot on
@nashezz, there are 2 compelling commercial reasons not to be in any hurry to announce additional indications -
1. IP position must be properly secured first.
2. Once you announce, you have given potential competitors a heads up. This may be particularly relevant given the terms of the Acadia licensing agreement where Acadia could do some quick preclinical work and call it an indication for trofinetide.
Tbh, the timing is not particularly important. The value is there and will be properly ascribed when BP comes looking.
(20min delay)